Zuclopenthixol

68 interactions 4 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Metoclopramide Injection Metoclopramide Nasal Spray Ofloxacin Otic Hydroxychloroquine Octreotide Injection Oxaliplatin Injection
2 Contraindicated 65 Major
All (68) Contraindicated (2) Major (65)

Contraindicated

Zuclopenthixol Metoclopramide Injection Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details Zuclopenthixol Metoclopramide Nasal Spray Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details

Major

Zuclopenthixol Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Zuclopenthixol Sertraline Explained Increased risk of QT interval prolongation and an increased CYP2D6 substrate exposure Details Zuclopenthixol Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Zuclopenthixol Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Zuclopenthixol Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Zuclopenthixol Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Zuclopenthixol Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Zuclopenthixol Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Zuclopenthixol Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Zuclopenthixol Azithromycin AzaSite An increased risk of QT interval prolongation Details Zuclopenthixol Abiraterone Abirtega Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Details Zuclopenthixol Alfuzosin UroXatral An increased risk of QT interval prolongation Details Zuclopenthixol Anagrelide Agrylin An increased risk of QT interval prolongation Details Zuclopenthixol Bedaquiline Sirturo An increased risk of QT interval prolongation Details Zuclopenthixol Chloroquine Aralen® An increased risk of QT interval prolongation Details Zuclopenthixol Dasatinib Phyrago An increased risk of QT interval prolongation Details Zuclopenthixol Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Zuclopenthixol Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Zuclopenthixol Disopyramide Norpace An increased risk of QT interval prolongation Details Zuclopenthixol Dofetilide Tikosyn An increased risk of QT interval prolongation Details Zuclopenthixol Dolasetron Anzemet An increased risk of QT interval prolongation Details Zuclopenthixol Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Zuclopenthixol Encorafenib Braftovi Increased risk of QT interval prolongation Details Zuclopenthixol Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Zuclopenthixol Eribulin Injection Halaven An increased risk of QT interval prolongation Details Zuclopenthixol Famotidine Calmicid An increased risk of QT interval prolongation Details Zuclopenthixol Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Zuclopenthixol Felbamate Felbatol An increased risk of QT interval prolongation Details Zuclopenthixol Flecainide Tambocor® An increased risk of QT interval prolongation Details Zuclopenthixol Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Zuclopenthixol Fostemsavir Rukobia Increased risk of torsade de pointes Details Zuclopenthixol Galantamine Razadyne An increased risk of QT interval prolongation Details Zuclopenthixol Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Zuclopenthixol Gemifloxacin Factive An increased risk of QT interval prolongation Details Zuclopenthixol Glasdegib Daurismo Increased risk of QT interval prolongation Details Zuclopenthixol Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Zuclopenthixol Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Zuclopenthixol Granisetron Injection Granisol An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.